[Skip to Navigation]
Sign In
Comment & Response
June 18, 2020

Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors

Author Affiliations
  • 1Department of Medical Oncology, University Medical Center Utrecht Cancer Center, Utrecht, the Netherlands
  • 2Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands
JAMA Oncol. 2020;6(8):1300-1301. doi:10.1001/jamaoncol.2020.1932

To the Editor With great interest, we read the article by Eggermont et al1 investigating the association between immune-related adverse events (irAEs) and recurrence-free survival (RFS) in patients with melanoma undergoing adjuvant treatment with pembrolizumab in the EORTC 1325/KEYNOTE-054 study. The authors convincingly showed that the occurrence of irAEs was associated with increased RFS. Strikingly, although mild irAEs, such as vitiligo and endocrine irAEs, were strongly associated with RFS, there was no significant association with severe (grade 3 or greater) irAEs.1

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words